Application | Comment | Organism |
---|---|---|
drug development | the enzyme is a target for the development of effective dual HIV-1 IN and RNase H inhibitors | Human immunodeficiency virus 1 |
Protein Variants | Comment | Organism |
---|---|---|
D443A | site-directed mutagenesis, altered inhibitor binding compared to wild-type enzyme | Human immunodeficiency virus 1 |
D549A | site-directed mutagenesis, altered inhibitor binding compared to wild-type enzyme | Human immunodeficiency virus 1 |
E478A | site-directed mutagenesis, altered inhibitor binding compared to wild-type enzyme | Human immunodeficiency virus 1 |
K540A | site-directed mutagenesis, altered inhibitor binding compared to wild-type enzyme | Human immunodeficiency virus 1 |
W535A | site-directed mutagenesis, altered inhibitor binding compared to wild-type enzyme | Human immunodeficiency virus 1 |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
additional information | binding mode and resistance profile for a dual-target pyrrolyl diketo acid scaffold against HIV-1 integrase and reverse-transcriptase-associated ribonuclease H (RNase H), using wild-type and mutant enzymes, and detail energy components contribution of calculated binding free energies of studied inhibitors binding to HIV-1 IN and RNase H wild-types and mutants, overview | Human immunodeficiency virus 1 |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Human immunodeficiency virus 1 | - |
HIV-1 | - |
Synonyms | Comment | Organism |
---|---|---|
reverse-transcriptase-associated ribonuclease H | - |
Human immunodeficiency virus 1 |
RNase H | - |
Human immunodeficiency virus 1 |
General Information | Comment | Organism |
---|---|---|
malfunction | two mutations in HIV-1 RNase H, Y501R and Y501W, result in a reduction of inhibitor potency, thus indicating their potential role in providing resistance to the inhibitor | Human immunodeficiency virus 1 |